Literature DB >> 21149247

Thrombotic microangiopathy in systemic lupus erythematosus: a cohort study in North Taiwan.

Ming-Han Chen1, Ming-Huang Chen, Wei-Sheng Chen, Peter Mu-Hsin Chang, Hui-Ting Lee, Hsiao-Yi Lin, De-Feng Huang.   

Abstract

OBJECTIVES: Thrombotic microangiopathy (TMA) co-existing with SLE is rarely reported. This study aimed to investigate the triggering factors, clinical features and outcomes of SLE patients with TMA in Northern Taiwan.
METHODS: Twenty-five TMA cases out of 2461 SLE patients admitted to Taipei Veterans General Hospital, between 2000 and 2010, were enrolled.
RESULTS: When TMA occurred, 16 (64.0%) patients had infection; 22 (88.0%) were in an active disease state with a SLEDAI score >10. Among the infection group, 13 (81.3%) had an increase in the SLEDAI score of ≥ 4. We found that older age (≥ 50 years), low platelets (≤ 20,000/nm(3)), presence of infection, acute renal failure (ARF) or four or more TMA features were independent risk factors for persistent haematological abnormalities (P < 0.05); older age (≥ 50 years) and a high reticulocyte index (>2%) were the risk factors for persistent renal function impairment (P < 0.05). The overall mortality rate was 52.0% (13 out of 25); older age (≥ 40 years), low complement value, presence of infection (P < 0.001), two or more infection sources, ARF and four or more TMA features were the statistically significant factors contributing to a higher mortality rate. Patients receiving plasma exchange seven times or more had a significantly higher rate of improvement in renal function and haematological abnormalities.
CONCLUSIONS: Our study showed that infection was one of the major triggers for the flare-up of SLE disease activity and occurrence of TMA in SLE. Infection is also a strong risk factor for outcome in SLE patients with TMA. Plasma exchange can be considered as an adjuvant treatment modality.

Entities:  

Mesh:

Year:  2010        PMID: 21149247     DOI: 10.1093/rheumatology/keq311

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  15 in total

1.  Renal thrombotic microangiopathy associated to worse renal prognosis in Lupus Nephritis.

Authors:  Fernando Louzada Strufaldi; Precil Diego Miranda de Menezes Menezes Neves; Cristiane Bitencourt Dias; Luis Yu; Viktoria Woronik; Livia Barreira Cavalcante; Denise Maria Avancini Costa Malheiros; Lectícia Barbosa Jorge
Journal:  J Nephrol       Date:  2021-02-11       Impact factor: 3.902

2.  Thrombotic microangiopathy due to multiple autoantibodies related to antiphospholipid syndrome.

Authors:  Shunsuke Noda; Masao Ogura; Akiko Tsutsumi; Tomohiro Udagawa; Koichi Kamei; Kentaro Matsuoka; Hiroshi Kitamura; Tatsuya Atsumi; Shuichi Ito
Journal:  Pediatr Nephrol       Date:  2011-12-31       Impact factor: 3.714

3.  TMA secondary to SLE: rituximab improves overall but not renal survival.

Authors:  Fangfang Sun; Xiaodong Wang; Wanlong Wu; Kaiwen Wang; Zhiwei Chen; Ting Li; Shuang Ye
Journal:  Clin Rheumatol       Date:  2017-08-30       Impact factor: 2.980

4.  Clinical characteristics, triggering etiologies, and response of plasmapheresis in thrombotic microangiopathy in Taiwan.

Authors:  Ching-Hu Chung; I-Jung Tsai; Min-Hua Tseng; Hsin-Hsu Chou; You-Lin Tain; Jeng-Daw Tsai; Yuan-Yow Chiou; Yee-Hsuan Chiou; Ching-Yuang Lin
Journal:  Medicine (Baltimore)       Date:  2021-05-21       Impact factor: 1.817

5.  A Case of Thrombotic Thrombocytopenia Purpura Associated with Systemic Lupus Erythematosus: Diagnostic Utility of ADAMTS-13 Activity.

Authors:  Risa Yamada; Kazuhisa Nozawa; Takashi Yoshimine; Yoshinari Takasaki; Hideoki Ogawa; Kenji Takamori; Iwao Sekigawa
Journal:  Autoimmune Dis       Date:  2011-07-11

Review 6.  Clinical evaluation of thrombotic microangiopathy: identification of patients with suspected atypical hemolytic uremic syndrome.

Authors:  Yu-Min Shen
Journal:  Thromb J       Date:  2016-10-04

Review 7.  Complement related kidney diseases: Recurrence after transplantation.

Authors:  Maurizio Salvadori; Elisabetta Bertoni
Journal:  World J Transplant       Date:  2016-12-24

8.  Eculizumab therapy on a patient with co-existent lupus nephritis and C3 mutation-related atypical haemolytic uremic syndrome: a case report.

Authors:  Mi Jung Kim; Haekyung Lee; Yon Hee Kim; So Young Jin; Hee-Jin Kim; Doyeun Oh; Jin Seok Jeon
Journal:  BMC Nephrol       Date:  2021-03-10       Impact factor: 2.388

9.  Plasmapheresis Is Associated With Better Renal Outcomes in Lupus Nephritis Patients With Thrombotic Microangiopathy: A Case Series Study.

Authors:  Qiu-Yu Li; Feng Yu; Fu-De Zhou; Ming-Hui Zhao
Journal:  Medicine (Baltimore)       Date:  2016-05       Impact factor: 1.889

10.  Effect of Thrombotic Microangiopathy on Clinical Outcomes in Indian Patients With Lupus Nephritis.

Authors:  N Pattanashetti; H Anakutti; R Ramachandran; M Rathi; A Sharma; R Nada; K L Gupta
Journal:  Kidney Int Rep       Date:  2017-04-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.